Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer
July 20, 2018 10:30 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving...
Significant Number of B-cell Maturation Antigen (BCMA) Targeted Therapies in Pipeline is Expected to Boost Market Growth
October 26, 2017 10:00 ET
|
Coherent Market Insights
SEATTLE, Oct. 26, 2017 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market (By product type: CAR-T cell, bispecific...
Triumvira to Present Corporate Update at the Bloom Burton & Co. Healthcare Investor Conference
April 25, 2016 08:30 ET
|
Triumvira Immunologics Inc.
HAMILTON, ON and HACKENSACK, NJ --(Marketwired - April 25, 2016) - Triumvira Immunologics Inc. today announced that its President and Chief Executive Officer Tony Fiorino, MD, PhD, will present a...